Opinion
Video
Author(s):
Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.
CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML
Revisit the OncLive On Air Episodes From February 2024
Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
OS Data Could Dictate Next Directions for Uproleselan in R/R AML
Decreased Azacitadine Dosing Shows Consistent Safety in Lower- and Intermediate-Risk MDS
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma